# Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

> **NCT01423851** · PHASE1,PHASE2 · COMPLETED · sponsor: **NS Pharma, Inc.** · enrollment: 77 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** NS-018

## Key facts

- **NCT ID:** NCT01423851
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2020-04-22
- **Final completion:** 2020-04-22
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423851, "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01423851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*